How to Cite
Abstract
Therapy after the implant of cardioverter-defibrillator in the primary and secundary prevention of sudden death during the first year of follow up in the a clinic of fourth level of complexity.Background: the implant of cardioverter-defibrillator has changes the pronostic in the primary and secondary prevention in the patients with suden death. There are a lot of evidence that supports that the therapies of the CDI (antitachycardia and shocks) have impact on the morbimortality of the patients with Implantable Cardioverter-Defibrillators, besides the effect proarritmogenic. Objective: It is for determining which is the incidence of appropriate and inappropriate therapies in our population of patients with Implantable Cardioverter-Defibrillators for primary and secondary prevention of sudden death. Materials and Methods: we describe a case series of patients with cardioverter-defibrillator as the primary and secondary prevention of sudden death in a clinic of fourth level of complexity. Results: the incidence of therapy of the Implantable Cardioverter-Defibrillators after implant in patients with primary and secondary prevention of sudden death to the first year of follow-up was 44 %. The incidence of apropiate therapy of the Implantable Cardioverter-Defibrillators after implant in patients with primary prevention of sudden death to the first year of follow-up was the 26,3 %.The incidence of apropiate therapy of the Implantable Cardioverter-Defibrillators after implant in patients with secondary prevention of sudden death to the first year of follow-up was the 53 %. The half of the patients with Implantable Cardioverter-Defibrillators afterimpant for primary prevention or secondary had apropiate therapies during the first year of follow - up.36 % of the patients presented inappropriate therapies during the year of follow-up after first implat of the Implantable Cardioverter-Defibrillators. Conclusions: The therapies after to the implant of cardioverter-Defibrillator were near to the half of the patients, being more frecuent in the secundary prevention. These events may be present in the different pathologies , and to be apropiate and inapropiate. The complications of procedure may be acutes and chronics. (MÉD.UIS. 2011;24(3):253-63).Key words: Implantable Cardioverter-Defibrillators . Sudden death. Primary prevention. Secondary prevention. Antitachycardia. Shocks.
References
2. Gónzales-Torrecilla E. Indicaciones actuales del desfibrilador automático implantable.. RevEspCardiolSupl. 2008;8:3A-8ª.
3. Zipes DP, Wyse DG, Friedman PL, Epstein AE, Hallstrom AP, Greene HL, et al. The AntiarrhythmicsVersus Implantable Defibrillators (AVID) Investigators. The AntiarrhythmicsVersus Implantable Defibrillators (AVID) Investigators. defibrillators in patients resucitated from near-fatal ventriculararrhythmias. N Engl J Med. 1997;337:1576-81.
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
5. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, HatalaR, et al. Prophylactic use of an implantable cardioverter-defibrillatorafter acute myocardial infarction. N Engl J Med 2004;351:2481-8.
6. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency andcauses of implantable cardioverter-defibrillator therapies: is devicetherapy proarrhythmic? Am J Cardiol 2006;97:1255– 61.
7. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH et al., Mortality after appropriateand inappropriate shocks in ScD-HeFT (abstr). Heart Rhythm 2006;3:S40.
8. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E et al., For the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 2006;113:776–82.
9. Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Clinical Practice Guidelines. ACC/HRS/AHA. J Am CollCardiol 2006;48:1064-1108.
10. Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995;92:1651– 64.
11. Vollmann D, Lüthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm 2005;2:307–9.
12. Healy E, Goyal S, Browning C, Browning C, Robotis D, Ramaswamy K, et al. Inappropriate ICD therapy dueto proarrhythmic ICD shocks and hyperpolarization. Pacing Clin Electrophysiol 2004;27:415– 6.
13. Taylor E, Berger R, Hummel JD, Dinerman JL, Kenknight B, Arria AM, et al. Analysis of patterns ofinitiation of sustained ventricular arrhythmias in patients with implantabledefibrillators. J Cardiovasc Electrophysiol 2000;11:719 –26.
14. Basu Ray I, Fendelander L, Singh JP. Cardiac resynchronizationtherapy and its potential proarrhythmic effect. Clin Cardiol 2007;30:498–502 .
15. Sweeney MO, Ruetz LL, Belk P, Mullen TJ, Johnson JW, Sheldon T.Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007;50:614 –22.